Aminoglycoside antibiotic

Netilmicin

Netilmicin is an aminoglycoside antibacterial used parenterally for serious Gram-negative infections, including some resistant to other aminoglycosides.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds to the bacterial 30S ribosomal subunit, causing misreading of the genetic code and inhibiting protein synthesis, giving a concentration-dependent bactericidal effect.

Prescribing in practice

Like all aminoglycosides it carries a dose- and duration-related risk of ototoxicity and nephrotoxicity, so therapeutic drug monitoring and renal function checks are essential.
Risk is increased in renal impairment, the elderly, with prolonged courses and with concurrent nephrotoxic or ototoxic drugs.
It should be avoided in myasthenia gravis as aminoglycosides can impair neuromuscular transmission.

Monitoring

Monitor serum drug concentrations, renal function and auditory/vestibular function during treatment, especially with longer courses.

Counselling the patient

Report any hearing loss, ringing in the ears, dizziness or reduced urine output.
Tell the team about any kidney problems or other medicines you take.

Evidence & guidelines

The need for level and renal monitoring with aminoglycosides is standard practice supported by the SPC and current prescribing references.

Reference: UK AMR; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Pathways